STAT+: Pharmalittle: We are reading about Catalent concerns, a congressional hearing, and more

The European Medicines Agency will investigate any risks to the availability of medicines processed at Catalent plants that will be sold to Novo Nordisk.
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks